67Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Norway
Neuroscience Intelligence
Norway neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #30 of 50 · Data maturity A · Research score 34.3 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
14Recruiting trials
113Publications
46Institutions
Executive interpretation
Norway ranks #30 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Norwegian University of Science and Technology51 recruiting
Oslo University Hospital42 recruiting
Haukeland University Hospital42 recruiting
Merck Sharp & Dohme LLC43 recruiting
University of Oslo41 recruiting
Nordlandssykehuset HF30 recruiting
Boehringer Ingelheim30 recruiting
University Hospital of North Norway30 recruiting
Diakonhjemmet Hospital20 recruiting
Novartis Pharmaceuticals20 recruiting
Disease activity
Parkinsons9trials
Adhd6trials
Alzheimers6trials
Depression5trials
Autism5trials
Epilepsy4trials
Migraine Headache3trials
Huntingtons2trials
Dementia Other2trials
Other Neurology2trials
Research institutions
Boehringer Ingelheim (Norway)OpenAlexlinked institution
Nordland Hospital TrustOpenAlexlinked institution
Østfold Hospital TrustOpenAlexlinked institution
Oslo Nye HøyskoleOpenAlexlinked institution
University Hospital of North NorwayOpenAlexlinked institution
Telemark HospitalOpenAlexlinked institution
Hedmark University CollegeOpenAlexlinked institution
Norwegian School of Sport SciencesOpenAlexlinked institution
Lovisenberg Diakonale SykehusOpenAlexlinked institution
Vestre Viken Hospital TrustOpenAlexlinked institution
Clinical evidence trail
NCT07298044A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisRECRUITING
NCT07021274DBT Skill Training for Autistic Adults With Difficulties in Emotion Regulation.RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06543914Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With MigraineACTIVE_NOT_RECRUITING
NCT06299189A Therapist Guided Internet-delivered Treatment for Adults With ADHD (Attention Deficit / Hyperactivity Disorder) - an Open Effectiveness Trial in Routine CareRECRUITING
NCT05839418Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)RECRUITING
NCT05218785Treatment of Gastrocnemius Tightness and Subsequent Chronic Plantar Fasciitis with Botulinum Toxin aRECRUITING
NCT05190172PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmasRECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
Research evidence trail
PUBMEDClinical insight in schizophrenia: Time-specific associations with symptoms, cognition and antipsychotic mechanisms.2027-01-01
PUBMEDInterstitial fluid rejuvenation through young-donor plasma exchange in cognitively impaired patients: a pilot safety and feasibility study.2026-12-01
PUBMEDInfection Risk During Rituximab Therapy in Multiple Sclerosis: Effect of Dosing Interval and Age.2026-12-01
PUBMEDDiagnostic-mortality discordance in ischaemic heart disease among patients with schizophrenia: A systematic review and meta-analysis.2026-12-01
PUBMEDGenomic relationship between polyendocrine metabolic ovarian syndrome and bipolar disorder.2026-11-01
PUBMEDThe burden of brain disorders in Norway: an analysis of data from the global burden of disease study 2023.2026-11-01
PUBMEDEmotion regulation difficulties in adults with ADHD and associations with insomnia symptoms.2026-10-15
PUBMEDNew and emerging therapeutics and molecular targets for attention-deficit hyperactivity disorder.2026-10-09
PUBMEDDeep brain stimulation for arm tremor: one-year blinded follow-up of a randomized trial.2026-10-09
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.